Compound Biejia Ruangan Tablets
Ingredients: Prepared Carapax Trionycis (Bie Jia), Curcuma Zedoaria (E Zhu), Red Peony Root (Chi Shao), Chinese Angelica (Dang Gui), Notoginseng (San Qi), Codonopsis (Dang Shen), Astragalus (Huang Qi), Human Placenta (Zi He Che), Cordyceps (Dong Chong Xia Cao), Isatis Root (Ban Lan Gen), Forsythia (Lian Qiao).
Functions and indications: Softens hardness and dissipates masses, invigorates blood and resolves stasis, clears toxins, and tonifies qi and nourishes blood. Indicated for chronic hepatitis B with liver fibrosis and early-stage cirrhosis characterized by blood stasis obstructing the collaterals, qi and blood deficiency, and residual internal heat toxins.
Clinical manifestations: Dull pain in the hypochondrium or palpable masses under the ribs, dark facial complexion, distention in the epigastrium and abdomen, poor appetite, loose stools, fatigue, dry mouth, bitter taste, and visible red threads in the sclera (indicative of heat toxin).
National "12th Five-Year Plan" and "13th Five-Year Plan" Major Science and Technology Projects Research
Compound Biejia Ruangan Tablets combined with antiviral drugs can significantly reduce the incidence of liver cancer
This achievement was published in the top hepatology journal Journal of Hepatology (IF 30.083). It is the first clinical study presenting high-level evidence in an international top-tier academic journal demonstrating that traditional Chinese medicine can reverse liver fibrosis and reduce liver cancer incidence. This work overcomes the longstanding lack of internationally recognized clinical evidence, especially regarding the most critical aspects of clinical efficacy and safety. It significantly elevates the status of traditional Chinese medicine in the global academic community and represents a groundbreaking milestone not only for hepatology but for the field of traditional Chinese medicine.
The research results provide a more effective treatment plan for the majority of hepatitis B patients, and are of great breakthrough significance for reducing the burden of health economy in China, improving the health level of the whole people, and further enhancing the overseas influence of traditional Chinese medicine.
Compound Biejia Ruangan Tablets significantly reduce the incidence of liver cancer
"Antiviral and Antifibrotic" therapy is not only highly effective, but also significantly improves the reversal rate of liver fibrosis, which is an effective treatment.
“Antiviral and Antifibrotic” therapydemonstrates safety
Non-toxic and no side effects
No additional burden on liver and kidneys
Good safety
Achievements of Researcher Zhang Yanqiong
Compound Biejia Ruangan Tablets significantly improve fibrosis progression and help prevent the development of liver cancer by modulating theceRNAnetwork
Researcher Zhang Yanqiong and her team at the Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, have discovered that the LncRNA-TUG1–microRNA-328-3p–SRSF9 mRNA axis is involved in the development of hepatocellular carcinoma (HCC).
The study further revealed that Compound Biejia Ruangan Tablets can regulate SRSF9 mRNA and miR-328-3p, thereby inhibiting the proliferation, migration, and cell cycle progression of HCC cells, while also inducing apoptosis;
This research was published in Molecular Cancer (Impact Factor: 41.444; JCR Quartile: Q1), one of the leading journals in the field of basic oncology research.
The study shows that
The LncRNA TUG1–miR-328-3p–SRSF9 mRNA axis may be involved in tumor growth in vivo and is effectively regulated by Compound Biejia Ruangan Tablets, which have been shown to significantly improve fibrosis progression and prevent the development of liver cancer.
The core network targets of Ruangan Tablets are involved in key modules
related to cancer development, immune regulation and inflammatory response, and metabolic processes.
They exert their effects in reversing the malignant "inflammation-to-cancer" transformation in the liver by targeting and modulating the PI3K/Akt/NF-κB signaling axis.
11 societies, 16 authoritativeguidelines/consensus clinical recommendations
Hepatology Branch of Chinese Medical Association, Infectious Diseases Branch of Chinese Medical Association, Gastroenterology Branch of Chinese Medical Association, Hepatobiliary Diseases Professional Committee of China Association of Chinese Medicine, Hepatology Professional Committee of China Medical Association of Minorities, Spleen and Stomach Diseases Branch of China Association of Chinese Medicine, Endoscopy Branch of Chinese Medical Association, Hepatology Professional Committee of Chinese Association of Integrative Medicine, and 11 other authoritative academic societies participated.
History
Originating from folk remedies
Ruangan Tablets showed effectiveness as early as 55 years ago.
Originating from folk prescriptions in northern rural areas, used to treat masses, pain syndromes, and liver ascites.
Three generations of experts, thirty years of development
Experts from three generations at PLA 302 Hospital optimized the formula based on folk remedies combined with Traditional Chinese Medicine (TCM) syndrome differentiation and clinical practice.
In 1977, after 10 years of clinical practice and adjustment, the prescription was formed with eleven Chinese herbs: Carapax Trionycis (Bie Jia), Chinese Angelica (Dang Gui), Red Peony Root (Chi Shao), Notoginseng (San Qi), Astragalus (Huang Qi), Codonopsis (Dang Shen), Cordyceps (Dong Chong Xia Cao), Human Placenta (Zi He Che), Isatis Root (Ban Lan Gen), Forsythia (Lian Qiao), and Curcuma Zedoaria (E Zhu).
Ruangan Tablets Launched
In 1997, the Ministry of Health designated "Compound Biejia Ruangan Tablets" for Phase II clinical trials, conducting multicenter, randomized, double-blinded clinical validation.
In 1999, China Food and Drug Administration (CFDA) approved Ruangan Tablets as a traditional Chinese medicine for treating liver fibrosis and cirrhosis caused by various chronic liver diseases. It became the world’s first anti-fibrosis Chinese traditional patent medicine and won the National Science and Technology Progress Award, Third Class.
A Classic National Medicine, Expert in Liver Treatment
Focused on liver disease, benefiting millions of patients.
Deeply engaged in treatment of liver fibrosis and cirrhosis, actively expanding into liver disease prevention, committed to becoming the leader in liver treatment in the major liver disease field.
2020: Major National Science and Technology Project of the 12th Five-Year Plan, "antiviral and antifibrotic" therapy reverses liver fibrosis;
2022: Major National Science and Technology Project of the 13th Five-Year Plan, "antiviral and antifibrotic" therapy reduces liver cancer incidence;
A classic national medicine, expert in liver treatment.
Themed Interviews
What was your original intention in designing the National Major Science and Technology Project during the 13th Five-Year Plan?
What is the significance of the achievements of the 13th Five-Year National Major Project for the development of Traditional Chinese Medicine (TCM), and what are the prospects in the field of liver diseases?
